AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
==== United States ==== In January 2009, an FDA advisory committee voted 14 to 12 against the continued marketing of propoxyphene products, based on its weak pain-killing abilities, addictiveness, association with drug deaths and possible heart problems, including arrhythmia. A subsequent re-evaluation resulted in a July 2009 recommendation to strengthen the boxed warning for propoxyphene to reflect the risk of overdose. Dextropropoxyphene subsequently carried a black box warning in the U.S., stating:
BMS-986121: μ-PAM BMS-986122: μ-PAM BPRMU191: confers agonistic properties to small-molecule morphinan antagonists Ignavine Oxytocin: μ-PAM δ-PAM (see reference) Cannabidiol Tetrahydrocannabinol Sodium (Na+)
Nihonium is the first member of the 7p series of elements and the heaviest group 13 element on the periodic table, below boron, aluminium, gallium, indium, and thallium. All the group 13 elements except boron are metals, and nihonium is expected to follow suit. Nihonium is predicted to show many differences from its lighter homologues. The major reason for this is the spin–orbit (SO) interaction, which is especially strong for the superheavy elements, because their electrons move much faster than in lighter atoms, at velocities close to the speed of light. In relation to nihonium atoms, it lowers the 7s and the 7p electron energy levels (stabilising those electrons), but two of the 7p electron energy levels are stabilised more than the other four. The stabilisation of the 7s electrons is called the inert pair effect, and the separation of the 7p subshell into the more and less stabilised parts is called subshell splitting. Computational chemists see the split as a change of the second, azimuthal quantum number l, from 1 to 1/2 and 3/2 for the more and less stabilised parts of the 7p subshell, respectively. The quantum number corresponds to the letter in the electron orbital name: 0 to s, 1 to p, 2 to d, etc. For theoretical purposes, the valence electron configuration may be represented to reflect the 7p subshell split as 7s2 7p1/21. The first ionisation energy of nihonium is expected to be 7.306 eV, the highest among the metals of group 13. Similar subshell splitting should exist for the 6d electron levels, with four being 6d3/2 and six being 6d5/2.
For example, metro stations in Pyongyang, North Korea, were constructed 110 metres (360 ft) below ground, and were designed to serve as nuclear shelters in the event of war, with each station entrance built with thick steel blast doors. An example of privately funded fallout shelters is the Ark Two Shelter in Ontario, Canada, and autonomous shelters have been constructed with an emphasis on post-war networking and reconstruction. In Switzerland, the majority of homes have an underground blast and fallout shelter. The country has an overcapacity of such shelters and can accommodate slightly more than the nation's population size. While the nuclear fallout shelters described above are the ideal long-term protection methods against dangerous radiation exposure in the event of a nuclear catastrophe, it is also necessary to have mobile protection equipment for medical and security personnel to safely assist in containment, evacuation, and many other necessary public safety objectives which ensue as a result of nuclear detonation. There are many basic shielding strategies used to protect against the deposition of radioactive material from external radiation environments. Respirators that protect against internal deposition are used to prevent the inhalation and ingestion of radioactive material and dermal protective equipment which is used to protect against the deposition of material on external structures like skin, hair, and clothing.
Sources: en.wikipedia.org
=== Actinium-227 === Actinium-227 is the most stable isotope of actinium, with a half-life of 21.772 years. It mainly (98.62%) undergoes beta decay, but sometimes (1.38%) it will undergo alpha decay instead. 227Ac is a member of the actinium series. It is found only in traces in uranium ores – one tonne of uranium in ore contains about 0.2 milligrams of 227Ac. 227Ac is prepared, in milligram amounts, by the neutron irradiation of 226Ra in a nuclear reactor.
=== Antibacterial activity === Lactoferrin's primary role is to sequester free iron, and in doing so remove essential substrate required for bacterial growth. Antibacterial action of lactoferrin is also explained by the presence of specific receptors on the cell surface of microorganisms. Lactoferrin binds to lipopolysaccharide of bacterial walls, and the oxidized iron part of the lactoferrin oxidizes bacteria via formation of peroxides. This affects the membrane permeability and results in the cell breakdown (lysis). Although lactoferrin also has other antibacterial mechanisms not related to iron, such as stimulation of phagocytosis, the interaction with the outer bacterial membrane described above is the most dominant and most studied. Lactoferrin not only disrupts the membrane, but even penetrates into the cell. Its binding to the bacteria wall is associated with the specific peptide lactoferricin, which is located at the N-lobe of lactoferrin and is produced by in vitro cleavage of lactoferrin with another protein, trypsin. A mechanism of the antimicrobial action of lactoferrin has been reported as lactoferrin targets H+-ATPase and interferes with proton translocation in the cell membrane, resulting in a lethal effect in vitro. Lactoferrin prevents the attachment of H. pylori in the stomach, which in turn, aids in reducing digestive system disorders. Bovine lactoferrin has more activity against H. pylori than human lactoferrin.
=== From vitamers === Animals are auxotroph for this enzyme co-factor and require it or an intermediate to be supplemented, hence its classification as a vitamin, unlike MoCo or CoQ10 for example. PLP is synthesized from pyridoxal by the enzyme pyridoxal kinase (gene PDXK), requiring one ATP molecule. PDXK can also produce 5'-phosphates of the other vitamers (pyridoxine and pyridoxamine), with pyridoxine 5′-phosphate oxidase converting these alternative 5'-phosphates into PLP. PLP is made and metabolized in the liver. PLP and other vitamin B6 phosphates can be broken down by pyridoxal phosphatase, which removes the phosphate group.
Sources: en.wikipedia.org
== Research == Gene therapy is currently being studied as a possible treatment for chronic granulomatous disease. CGD is well-suited for gene therapy since it is caused by a mutation in single gene which only affects one body system (the hematopoietic system). Viruses have been used to deliver a normal gp91 gene to rats with a mutation in this gene, and subsequently the phagocytes in these rats were able to produce oxygen radicals. In 2006, two human patients with X-linked chronic granulomatous disease underwent gene therapy and blood cell precursor stem cell transplantation to their bone marrow. Both patients recovered from their CGD, clearing pre-existing infections and demonstrating increased oxidase activity in their neutrophils. However, long-term complications and efficacy of this therapy were unknown. In 2012, a 16-year-old boy with CGD was treated at the Great Ormond Street Hospital, London with an experimental gene therapy that temporarily reversed the CGD and allowed him to overcome a life-threatening lung disease. In 2024, Prime Medicine began a Phase 1/2 open-label clinical trial to evaluate PM359, an investigational gene therapy, in patients with CGD caused by NCF1 mutations. The treatment involves transplantation of autologous CD34+ stem cells modified by prime editing ex vivo. Following an announcement of preliminary results in May 2025, Prime Medicine and its clinical collaborators reported in December 2025 that two CGD patients treated with PM359 had been "effectively cured" of the disease.
If prolonged, or severe, it can cause coma and death regardless of cause. For a person with diabetes, this can be caused by insufficient glucose absorption (e.g. from inadequate insulin) combined with metabolic ketosis. It can lead to diabetic ketoacidosis, a medical emergency. Acute Happens for a limited period of time; abrupt onset; sharp, severe. Adrenal gland An endocrine gland located on top of the human kidney. Secretes adrenaline, one of the primary 'fight or flight' stress hormones, which have substantial counterregulatory effects. Adverse effect A harmful result. Albuminuria release of the protein albumin in urine. As this protein is strongly conserved, this is evidence of abnormal kidney function. Aldose reductase inhibitor Alpha cell one of the types of cell in the pancreas (in areas called the Islets of Langerhans). Alpha cells make and release a hormone called glucagon, which raises the level of glucose (sugar) in the blood. Amino acid a weak acid carbon compound containing carbon, hydrogen, oxygen, and nitrogen. The nitrogenous amine group is characteristic of each. Amino acids are the building blocks of protein and there are about 20 used in the human body, of which about half can be constructed internally. The rest must come in the diet—they are the essential amino acids. Amyotrophy A type of diabetic neuropathy that causes muscle weakness and wasting. Amylin A peptide thought to be involved in beta cell loss in type 2 diabetes. Angiopathy A process that damages the blood vessels.
The 2014 Ebola outbreak killed more than 11,300 people. In the Democratic Republic of Congo (DRC), as of January 2020, this is the second largest outbreak with over 3,400 confirmed or probable cases, including more than 2,200 deaths. Regeneron used its VelociGene, VelocImmune, and VelociMab antibody discovery and production technologies and coordinated with the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). The therapy was developed in 6 months and a Phase 1 trial in healthy humans was completed in 2015.
The functional form of single-stranded RNA molecules, just like proteins, frequently requires a specific spatial tertiary structure. The scaffold for this structure is provided by secondary structural elements that are hydrogen bonds within the molecule. This leads to several recognizable "domains" of secondary structure like hairpin loops, bulges, and internal loops. In order to create, i.e., design, RNA for any given secondary structure, two or three bases would not be enough, but four bases are enough. This is likely why nature has "chosen" a four base alphabet: fewer than four would not allow the creation of all structures, while more than four bases are not necessary to do so. Since RNA is charged, metal ions such as Mg2+ are needed to stabilise many secondary and tertiary structures. The naturally occurring enantiomer of RNA is D-RNA composed of D-ribonucleotides. All chirality centers are located in the D-ribose. By the use of L-ribose or rather L-ribonucleotides, L-RNA can be synthesized. L-RNA is much more stable against degradation by RNase. Like other structured biopolymers such as proteins, one can define topology of a folded RNA molecule. This is often done based on arrangement of intra-chain contacts within a folded RNA, termed as circuit topology.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.